PSMB2

Across TCGA pan-cancer cohorts, PSMB2 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated PSMB2 data layer compared with 2 for mutation status and 7 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PSMB2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PSMB2 expression acts as an unfavorable survival marker, although some lineages such as COAD and READ show a favorable association.

LIHC, ACC, and MESO are the cancer types where PSMB2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.417	0.604	<.001	78	view →
ACC	OS	Tertile	II,III,IV	0.720	0.971	<.001	75	view →
MESO	OS	Quartile	All	0.363	0.675	<.001	73	view →
COAD	DFS	Median	IV	0.613	0.334	.001	56	view →
LGG	DFS	Median	All	0.644	0.837	<.001	54	view →
KIRP	DFS	Tertile	All	0.511	1.000	<.001	51	view →
READ	DFS	Tertile	All	0.904	0.694	.004	37	view →
BRCA	OS	Quartile	III,IV	0.705	0.895	.001	34	view →
LAML	DFS	Quartile	All	0.292	0.718	.004	34	view →
HNSC	OS	Tertile	III,IV	0.464	0.606	.009	22	view →
SARC	DFS	Quartile	All	0.527	0.743	.001	19	view →
ESCA	OS	Median	III,IV	0.446	0.673	.017	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

PSMB2–LIHC (OS)

Open the LIHC breakdown →